LOIS M RAMONDETTA to Endometrial Neoplasms
This is a "connection" page, showing publications LOIS M RAMONDETTA has written about Endometrial Neoplasms.
Connection Strength
2.164
-
Endometrial cancer patients understanding and interest in weight loss surgery. Gynecol Oncol. 2023 08; 175:88-92.
Score: 0.449
-
Lymphadenectomy during endometrial cancer staging: practice patterns among gynecologic oncologists. Gynecol Oncol. 2010 Nov; 119(2):291-4.
Score: 0.184
-
In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines. Cancer Chemother Pharmacol. 2008 Aug; 62(3):483-9.
Score: 0.152
-
Practice patterns of SGO members for stage IIIA endometrial cancer. Gynecol Oncol. 2005 Jul; 98(1):77-83.
Score: 0.129
-
Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol. 2021 07; 162(1):24-31.
Score: 0.097
-
Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15.
Score: 0.092
-
Mesonephric-like Carcinoma of the Endometrium: A Subset of Endometrial Carcinoma With an Aggressive Behavior. Am J Surg Pathol. 2020 04; 44(4):429-443.
Score: 0.090
-
Endometrial cancer in polyps associated with tamoxifen use. Am J Obstet Gynecol. 1999 Feb; 180(2 Pt 1):340-1.
Score: 0.083
-
A comparative analysis of Ki-67, p53, and p21WAF1CIP1 expression in tamoxifen associated endometrial carcinomas. Anticancer Res. 1998 Nov-Dec; 18(6B):4661-5.
Score: 0.081
-
Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. Obstet Gynecol. 2018 01; 131(1):109-116.
Score: 0.077
-
Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study. Gynecol Oncol. 2016 Dec; 143(3):466-471.
Score: 0.071
-
A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium. Gynecol Oncol. 2013 May; 129(2):304-9.
Score: 0.055
-
Prospective evaluation of insulin resistance among endometrial cancer patients. Am J Obstet Gynecol. 2011 Apr; 204(4):355.e1-7.
Score: 0.048
-
Morphoproteomic analysis reveals an overexpressed and constitutively activated phospholipase D1-mTORC2 pathway in endometrial carcinoma. Int J Clin Exp Pathol. 2010 Nov 20; 4(1):13-21.
Score: 0.047
-
Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial. Cancer. 2010 Nov 01; 116(21):4973-9.
Score: 0.047
-
A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010 Dec 01; 116(23):5415-9.
Score: 0.046
-
Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol. 2009 Oct; 115(1):6-11.
Score: 0.043
-
Physical activity and obesity in endometrial cancer survivors: associations with pain, fatigue, and physical functioning. Am J Obstet Gynecol. 2009 Mar; 200(3):288.e1-8.
Score: 0.041
-
In vitro evaluation of the effects of gefitinib on the cytotoxic activity of selected anticancer agents in a panel of human endometrial cancer cell lines. J Oncol Pharm Pract. 2009 Mar; 15(1):35-44.
Score: 0.040
-
Radiation-associated endometrial cancers are prognostically unfavorable tumors: a clinicopathologic comparison with 527 sporadic endometrial cancers. Gynecol Oncol. 2006 Dec; 103(3):948-51.
Score: 0.035
-
Determination of the mechanism of gemcitabine modulation of cisplatin drug resistance in panel of human endometrial cancer cell lines. Gynecol Oncol. 2006 Nov; 103(2):518-22.
Score: 0.034
-
Estrogen and progesterone receptors and cyclooxygenase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium. Gynecol Oncol. 2005 May; 97(2):483-8.
Score: 0.032
-
Heterogeneity of stage IIIA endometrial carcinomas: implications for adjuvant therapy. Int J Gynecol Cancer. 2005 May-Jun; 15(3):510-6.
Score: 0.032
-
Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. Gynecol Oncol. 2004 Oct; 95(1):32-6.
Score: 0.031
-
An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines. Gynecol Oncol. 2004 Jan; 92(1):314-9.
Score: 0.029
-
Development of endometrial cancer after radiation treatment for cervical carcinoma. Obstet Gynecol. 2003 May; 101(5 Pt 1):941-5.
Score: 0.028
-
PTEN expression in tamoxifen-associated endometrial cancers. Anticancer Res. 2002 Sep-Oct; 22(5):2945-8.
Score: 0.027
-
A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation. Support Care Cancer. 2021 Jan; 29(1):213-222.
Score: 0.023
-
Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer. Clin Cancer Res. 2000 Jan; 6(1):278-84.
Score: 0.022